Antigen delivery system
A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.
1. A minimal antigen delivery system consisting essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class I restricted peptide and surface-modified with a cancer-specific cell targeting peptide which mediates binding and internalization of the liposomes into a target cell, wherein the HLA class I restricted peptide is a vaccine-dependent, secondary immunogenic HLA class I restricted peptide.
2. The system of claim 1 , wherein the antigen is a vaccine-dependent, secondary immunogenic HLA class I restricted peptide, that is measles virus hemagglutinin peptide H250.
3. The system of claim 1 , wherein the antigen is a vaccine-dependent, secondary immunogenic HLA class I restricted peptide, that is smallpox virus H-2Kd-restricted vaccinia-specific peptide, A5275-83 (VACV-A52).
4. The system of claim 1 , wherein the cell-targeting peptide is H1299.3.
5. The system of claim 2 , wherein the cell-targeting peptide is H1299.3.
6. The system of claim 3 , wherein the cell-targeting peptide is H1299.3.
7. The system of claim 1 that does not comprise any viral particles, toxins, or biologically-derived material.
8. A method of making an antigen delivery system of claim 1 , comprising the step(s) of: surface modifying the PEGylated stealth liposomes loaded with the HLA class I restricted peptide by conjugating to the surface the cell targeting peptide.
9. A method of making an antigen delivery system of claim 1 , comprising the step(s) of:
loading the PEGylated stealth liposomes by forming the liposomes in the presence of the class restricted peptide; and
surface modifying the PEGylated stealth liposomes loaded with the HLA class I restricted peptide by conjugating to the surface the cell targeting peptide.
10. A method of using the antigen delivery system of claim 1 , comprising the step(s) of: introducing the antigen delivery system into a host in need thereof.
11. A method of using the antigen delivery system of claim 1 , comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell.
12. A method of using the antigen delivery system of claim 2 , comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell.
13. A method of using the antigen delivery system of claim 3 , comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell.
14. A method of using the antigen delivery system of claim 4 , comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell.
15. A method of using the antigen delivery system of claim 5 , comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell.
16. A method of using the antigen delivery system of claim 6 , comprising the step(s) of: introducing the antigen delivery system into a person in need thereof, and detecting a resultant secondary immune response or inhibition of the target cell.